These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28970009)

  • 1. Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes.
    Shibata H; Nishimura K; Miyama C; Tada M; Suzuki T; Saito Y; Ishii-Watabe A
    J Immunol Methods; 2018 Jan; 452():73-77. PubMed ID: 28970009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing.
    Mytych DT; Barger TE; King C; Grauer S; Haldankar R; Hsu E; Wu MM; Shiwalkar M; Sanchez S; Kuck A; Civoli F; Sun J; Swanson SJ
    J Immunol Methods; 2012 Aug; 382(1-2):129-41. PubMed ID: 22634015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study.
    Wadhwa M; Mytych DT; Bird C; Barger T; Dougall T; Han H; Rigsby P; Kromminga A; Thorpe R;
    J Immunol Methods; 2016 Aug; 435():32-42. PubMed ID: 27173074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J; Schantz A; Schwegler M; Shankar G
    J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins.
    Hu J; Wala I; Han H; Nagatani J; Barger T; Civoli F; Kaliyaperumal A; Zhuang Y; Gupta S
    J Immunol Methods; 2015 Apr; 419():1-8. PubMed ID: 25795420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms.
    Liang M; Klakamp SL; Funelas C; Lu H; Lam B; Herl C; Umble A; Drake AW; Pak M; Ageyeva N; Pasumarthi R; Roskos LK
    Assay Drug Dev Technol; 2007 Oct; 5(5):655-62. PubMed ID: 17939757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
    Weeraratne DK; Lofgren J; Dinnogen S; Swanson SJ; Zhong ZD
    J Immunol Methods; 2013 Oct; 396(1-2):44-55. PubMed ID: 23933325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison.
    Barger TE; Kuck AJ; Chirmule N; Swanson SJ; Mytych DT
    Nephrol Dial Transplant; 2012 Feb; 27(2):688-93. PubMed ID: 21602184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeutic.
    Dysinger M; King LE
    J Immunol Methods; 2012 May; 379(1-2):30-41. PubMed ID: 22414486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of anti-drug monoclonal antibody panels against adalimumab and infliximab.
    Suzuki T; Tada M; Ishii-Watabe A
    Biologicals; 2020 Jan; 63():39-47. PubMed ID: 31883741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype.
    Wu Y; Liu X; Chen Y; Woods R; Lee N; Yang H; Chowdhury P; Roskos LK; White WI
    J Pharm Biomed Anal; 2013 Dec; 86():73-81. PubMed ID: 23988731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.
    Wyant T; Yang L; Rosario M
    AAPS J; 2020 Nov; 23(1):3. PubMed ID: 33200296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-step, high throughput, and highly reproducible method for measuring IgM quantity and avidity directly from fish serum via biolayer interferometry (BLI).
    Li A; Harris RJ; Fry BG; Barnes AC
    Fish Shellfish Immunol; 2021 Dec; 119():231-237. PubMed ID: 34626789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of an anti-rituximab monoclonal antibody panel.
    Tada M; Suzuki T; Ishii-Watabe A
    MAbs; 2018 Apr; 10(3):370-379. PubMed ID: 29309213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
    Grasmeier MK; Weber S; Treiber M; Thaler MA; Luppa PB
    Clin Chem Lab Med; 2023 Jun; 61(7):1255-1265. PubMed ID: 36753693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an anti-EPO antibody detection kit based on lab-on-a-chip and bridging antibody technologies.
    Oh JG; Seong J; Han S; Heo TH
    Biologicals; 2018 Jul; 54():8-12. PubMed ID: 29779958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.